Literature DB >> 17013976

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.

Birgit Scheel1, Steffen Aulwurm, Jochen Probst, Lothar Stitz, Ingmar Hoerr, Hans-Georg Rammensee, Michael Weller, Steve Pascolo.   

Abstract

Stabilized synthetic RNA oligonucleotides (ORN) and protected messenger RNA (mRNA) were recently discovered to possess an immunostimulatory capacity through their recognition by TLR 7 and 8. We wanted to find out whether this danger signal is capable of triggering anti-tumor immunity when injected locally into an established tumor. Using the mouse glioma tumor cell line SMA-560 in syngenic VM/Dk mice, we were able to show that intra-tumor injections of protamine-stabilized mRNA do indeed induce tumor regression and long-term anti-tumor immunity. Residual RNA-injected tumors show CD8 infiltration. Distant injections of protamine-protected mRNA and intra-tumor injection of naked mRNA also result in anti-tumor immunity. Although they are strong danger signals, RNA are labile molecules with a short half-life: they do not trigger side effects such as long-term, uncontrolled immunostimulation evidenced by splenomegaly in CpG DNA-treated mice. In conclusion, RNA molecules are potent and safe danger signals that are relevant for active immunotherapy strategies aimed at the eradication of solid tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17013976     DOI: 10.1002/eji.200635910

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  41 in total

Review 1.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

Review 2.  Toll-like receptors and cancer.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Nat Rev Cancer       Date:  2008-12-04       Impact factor: 60.716

3.  A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery.

Authors:  David N Nguyen; Phillip Kim; Luis Martínez-Sobrido; Brett Beitzel; Adolfo García-Sastre; Robert Langer; Daniel G Anderson
Journal:  Biotechnol Bioeng       Date:  2009-07-01       Impact factor: 4.530

4.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Authors:  David N Nguyen; Kerry P Mahon; Ghania Chikh; Phillip Kim; Hattie Chung; Alain P Vicari; Kevin T Love; Michael Goldberg; Steve Chen; Arthur M Krieg; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

Review 5.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

6.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 7.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01

8.  In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma.

Authors:  W Maes; C Deroose; V Reumers; O Krylyshkina; R Gijsbers; V Baekelandt; J Ceuppens; Z Debyser; S W Van Gool
Journal:  J Neurooncol       Date:  2008-09-12       Impact factor: 4.130

9.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

10.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

Authors:  Ans De Beuckelaer; Charlotte Pollard; Sandra Van Lint; Kenny Roose; Lien Van Hoecke; Thomas Naessens; Vimal Kumar Udhayakumar; Muriel Smet; Niek Sanders; Stefan Lienenklaus; Xavier Saelens; Siegfried Weiss; Guido Vanham; Johan Grooten; Stefaan De Koker
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.